Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Tibolone
Therapeutic Area : Musculoskeletal
Study Phase : Approved FDF
Recipient : Mithra Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Mithra Signs LSA for Commercialization of Tibelia® in Liechtenstein and Switzerland
Details : Developed by Mithra as the bioequivalent version of Livial® Tibelia® is a complex oral formulation composed of tibolone. Under the terms of this agreement, Spirig Healthcare AG will be responsible for the commercialization of Tibelia® in Liechtenstein...
Product Name : Tibelia
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
November 06, 2020
Lead Product(s) : Tibolone
Therapeutic Area : Musculoskeletal
Highest Development Status : Approved FDF
Recipient : Mithra Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Resiquimod
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 11, 2013
Lead Product(s) : Resiquimod
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sertaconazole Nitrate
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sertaconazole 2% Cream to Improve Symptoms Associated With Atopic Dermatitis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 15, 2013
Lead Product(s) : Sertaconazole Nitrate
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Resiquimod
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 24, 2012
Lead Product(s) : Resiquimod
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
